search
Back to results

Actos Now for Prevention of Diabetes (ACT NOW)

Primary Purpose

Impaired Glucose Tolerance, Type 2 Diabetes

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Pioglitazone
Placebo
Sponsored by
The University of Texas Health Science Center at San Antonio
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Impaired Glucose Tolerance focused on measuring Impaired Glucose Tolerance, Type 2 Diabetes, Prevention, Pioglitazone

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Men and women All ethnic groups 18 years of age and older Impaired glucose tolerance by glucose tolerance test (fasting glucose 95-125 mg/dl and 2 hr glucose of 140-199 mg/dl) At least one of the following: One or more components of the insulin resistance syndrome (HDL < 40 mg/dl in females and <35 mg/dl in males, fasting triglycerides > 150 mg/dl, blood pressure > 135/85 mmHg, BMI > 24 kg/m2, waist circumference > 102 cm in men and > 88 cm in women) One or more first degree relatives with type 2 diabetes History of gestational diabetes Polycystic ovarian disease Minority ethnic background (Mexican American, African American, Asian and Pacific Islanders, Native American) Exclusion Criteria: Type 2 diabetes Previously treated with thiazolidinediones (ever) or metformin (within one year) Previously treated with a sulfonylurea, a meglitinide, an alpha glucosidase inhibitor for more than a week within last year or within the 3 months prior to randomization Previously treated with insulin (other than during pregnancy) for more than one week within the last year or within the 3 months prior to randomization Cardiovascular disease Hospitalization for treatment of heart disease or stroke in past 6 months New York Heart Association Functional Class > 2 Left bundle branch block or third degree AV block Aortic stenosis SBP > 180 mmHg or DBP > 105 mmHg Renal disease Anemia Hepatitis GI diseases (pancreatitis, inflammatory bowel disease) Recent or significant abdominal surgery Advanced pulmonary disease Chronic infections Weight loss > 10% in past 6 months Pregnancy and childbearing Major psychiatric disorders Excessive alcohol intake Thiazide use > 25 mg per day Non-selective beta blockers Niacin Systemic glucocorticoids Weight loss or weight gain medication Thyroid disease-suboptimally treated Active endocrine diseases (Cushing's, acromegaly) Plasma triglycerides over 400 mg/dl (despite treatment) History bladder cancer Hematuria

Sites / Locations

  • Carl T. Hayden VA Medical Center
  • USC-Keck School of Medicine
  • University of California San Diego-San Diego VA Medical Center
  • Georgetown University
  • Pennington Biomedical Research Center
  • SUNY Health Science Center
  • University of Tennessee
  • Texas Diabetes Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo

Pioglitazone

Arm Description

Placebo tablet similar to pioglitazone tablet

Pioglitazone tablet similar to placebo tablet

Outcomes

Primary Outcome Measures

Prevention of Type 2 Diabetes
Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization

Secondary Outcome Measures

Change From Baseline in Fasting Plasma Glucose of 2.4 Years
Fasting Plasma Glucose
Change From Baseline in Plasma Insulin Concentration During Oral Glucose Tolerance Test
Insulin secretion
Change From Baseline in Matsuda Index of Insulin Sensitivity (There Are no Minimum/Maximum Values)
Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity.
Change in Atherosclerosis
carotid intima thickness

Full Information

First Posted
September 14, 2005
Last Updated
June 29, 2016
Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
University of Texas, Takeda Pharmaceuticals North America, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00220961
Brief Title
Actos Now for Prevention of Diabetes (ACT NOW)
Official Title
Actos Now for Prevention of Diabetes (ACT NOW)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2016
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
April 2010 (Actual)
Study Completion Date
April 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
University of Texas, Takeda Pharmaceuticals North America, Inc.

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to examine whether pioglitazone versus placebo can reduce the conversion rate of impaired glucose tolerance (IGT) to type 2 diabetes mellitus
Detailed Description
IGT is a prediabetic state. If IGT can be prevented from progressing to overt diabetes, the hyperglycemia-related complications of this devastating disease can be prevented. Subjects with IGT will be identified with an oral glucose tolerance test (OGTT). Eligible subjects also will have a measurement of first phase insulin secretion and insulin sensitivity using the frequently sampled intravenous glucose tolerance test (FSIVGTT) and carotid intimal media thickness using carotid ultrasound. Following these measurements subjects will be randomized to receive pioglitazone or placebo and they will return every 3 months for determination of fasting plasma glucose (FPG) concentration and interim medical history. Recruitment will take place over 15 months. From the time that the recruitment period ends, subjects will be followed for a total of 24 months on pioglitazone or placebo. The OGTT will be repeated at 15,27, and 39 months, or if the FPG is ≥ 126 mg/dl on the 3-month follow up visits. If the diagnosis of diabetes is established before month 39 or at month 39, the FSIVGTT and carotid ultrasound will be repeated. At 39 months, subjects will be washed out of pioglitazone or placebo and the OGTT, FSIVGTT, and carotid ultrasound will be repeated at month 45.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Impaired Glucose Tolerance, Type 2 Diabetes
Keywords
Impaired Glucose Tolerance, Type 2 Diabetes, Prevention, Pioglitazone

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
602 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo tablet similar to pioglitazone tablet
Arm Title
Pioglitazone
Arm Type
Active Comparator
Arm Description
Pioglitazone tablet similar to placebo tablet
Intervention Type
Drug
Intervention Name(s)
Pioglitazone
Other Intervention Name(s)
Actos
Intervention Description
Pioglitazone tablets - 45 mg/day
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo tablets similar to pioglitazone tablets - 1 tablet/day
Primary Outcome Measure Information:
Title
Prevention of Type 2 Diabetes
Description
Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization
Time Frame
2.4 years
Secondary Outcome Measure Information:
Title
Change From Baseline in Fasting Plasma Glucose of 2.4 Years
Description
Fasting Plasma Glucose
Time Frame
Baseline versus 2.4 years
Title
Change From Baseline in Plasma Insulin Concentration During Oral Glucose Tolerance Test
Description
Insulin secretion
Time Frame
Baseline versus 2.4 years
Title
Change From Baseline in Matsuda Index of Insulin Sensitivity (There Are no Minimum/Maximum Values)
Description
Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity.
Time Frame
Baseline versus 2.4 years
Title
Change in Atherosclerosis
Description
carotid intima thickness
Time Frame
Baseline versus 2.4 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men and women All ethnic groups 18 years of age and older Impaired glucose tolerance by glucose tolerance test (fasting glucose 95-125 mg/dl and 2 hr glucose of 140-199 mg/dl) At least one of the following: One or more components of the insulin resistance syndrome (HDL < 40 mg/dl in females and <35 mg/dl in males, fasting triglycerides > 150 mg/dl, blood pressure > 135/85 mmHg, BMI > 24 kg/m2, waist circumference > 102 cm in men and > 88 cm in women) One or more first degree relatives with type 2 diabetes History of gestational diabetes Polycystic ovarian disease Minority ethnic background (Mexican American, African American, Asian and Pacific Islanders, Native American) Exclusion Criteria: Type 2 diabetes Previously treated with thiazolidinediones (ever) or metformin (within one year) Previously treated with a sulfonylurea, a meglitinide, an alpha glucosidase inhibitor for more than a week within last year or within the 3 months prior to randomization Previously treated with insulin (other than during pregnancy) for more than one week within the last year or within the 3 months prior to randomization Cardiovascular disease Hospitalization for treatment of heart disease or stroke in past 6 months New York Heart Association Functional Class > 2 Left bundle branch block or third degree AV block Aortic stenosis SBP > 180 mmHg or DBP > 105 mmHg Renal disease Anemia Hepatitis GI diseases (pancreatitis, inflammatory bowel disease) Recent or significant abdominal surgery Advanced pulmonary disease Chronic infections Weight loss > 10% in past 6 months Pregnancy and childbearing Major psychiatric disorders Excessive alcohol intake Thiazide use > 25 mg per day Non-selective beta blockers Niacin Systemic glucocorticoids Weight loss or weight gain medication Thyroid disease-suboptimally treated Active endocrine diseases (Cushing's, acromegaly) Plasma triglycerides over 400 mg/dl (despite treatment) History bladder cancer Hematuria
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ralph A. DeFronzo, M.D.
Organizational Affiliation
Texas Diabetes Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Carl T. Hayden VA Medical Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85012
Country
United States
Facility Name
USC-Keck School of Medicine
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Facility Name
University of California San Diego-San Diego VA Medical Center
City
San Diego
State/Province
California
ZIP/Postal Code
92161
Country
United States
Facility Name
Georgetown University
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States
Facility Name
Pennington Biomedical Research Center
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70808
Country
United States
Facility Name
SUNY Health Science Center
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11203
Country
United States
Facility Name
University of Tennessee
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38163
Country
United States
Facility Name
Texas Diabetes Institute
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78207
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
33210751
Citation
Ipsen EO, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, Hemmingsen B. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.
Results Reference
derived
PubMed Identifier
26982008
Citation
Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA. Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW. J Clin Endocrinol Metab. 2016 May;101(5):2056-62. doi: 10.1210/jc.2015-4202. Epub 2016 Mar 16.
Results Reference
derived
PubMed Identifier
25603459
Citation
Tripathy D, Cobb JE, Gall W, Adam KP, George T, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Reaven PD, Musi N, Ferrannini E, DeFronzo RA. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. J Clin Endocrinol Metab. 2015 May;100(5):1855-62. doi: 10.1210/jc.2014-3824. Epub 2015 Jan 20.
Results Reference
derived
PubMed Identifier
24705615
Citation
Tripathy D, Clement SC, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA. Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. Diabetes Care. 2014 Jun;37(6):1706-11. doi: 10.2337/dc13-1745. Epub 2014 Apr 4.
Results Reference
derived
PubMed Identifier
23175674
Citation
Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, Bray GA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Tripathy D, DeFronzo RA, Reaven PD. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):393-9. doi: 10.1161/ATVBAHA.112.300346. Epub 2012 Nov 21. Erratum In: Arterioscler Thromb Vasc Biol. 2013 May;33(5):e114.
Results Reference
derived
PubMed Identifier
21428766
Citation
DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011 Mar 24;364(12):1104-15. doi: 10.1056/NEJMoa1010949. Erratum In: N Engl J Med. 2011 Jul 14;365(2):189. N Engl J Med. 2011 Sep 1;365(9):869.
Results Reference
derived
PubMed Identifier
19640291
Citation
Defronzo RA, Banerji M, Bray GA, Buchanan TA, Clement S, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner R, Reaven PD, Schwenke D, Stentz FB, Tripathy D. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord. 2009 Jul 29;9:17. doi: 10.1186/1472-6823-9-17.
Results Reference
derived
Links:
URL
http://www.diabetes.org/
Description
American Diabetes Association

Learn more about this trial

Actos Now for Prevention of Diabetes (ACT NOW)

We'll reach out to this number within 24 hrs